Wednesday, February 19, 2020

WuXi STA Shanghai & Changzhou Facilities Pass U.S. FDA Inspections

SHANGHAI, 24 July, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announces that its Analytical Service Unit (ASU) in Shanghai and active pharmaceutical ingredient (API) process R&D...

WuXi AppTec Named One of MIT Technology Review’s 50 Smartest Companies

  Shanghai, June 29, 2019 – WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announces that it has been...

WuXi AppTec’s Enabling Capability Recognized by Partners and Philadelphia Authority at BIO 2019

By WuXi Content Team WuXi AppTec’s enabling capabilities and contribution to the development of life science were recognized by both its many partners and the City of Philadelphia at the BIO International...

insitro’s Daphne Koller Discusses Machine Learning, Predictive Biology and Therapeutic Approaches for Nonalcoholic Steatohepatitis...

By Rich Soll, Senior Advisor, Strategic Initiatives, WuXi AppTec (@richsollwx) insitro’s CEO Daphne Koller is no stranger to the world of experimental biology. As the Rajeev Motwani of Professor of Computer Science...

Subscribe to our Newsletter

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS

Amicus Therapeutics: A Patient-First Approach to Treating Rare Diseases

Rare diseases have long posed a dual challenge. First, since there are relatively few patients by definition, they are not the highest priority for...